What it's for (Indications)
- Aminophylline hydrate is a xanthine derivative primarily indicated for the symptomatic treatment and prophylaxis of reversible bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, and bronchial asthma.
- It is often employed in acute exacerbations when rapid bronchodilation is required, particularly in hospitalized patients, and can also be used for long-term management in patients whose symptoms are not adequately controlled by other bronchodilator therapies.
- Its utility is typically reserved for situations where first-line agents like beta-agonists or corticosteroids are insufficient or contraindicated, given its narrow therapeutic index and potential for significant adverse effects.
- The therapeutic decision to initiate aminophylline should always be weighed against the potential risks and the availability of safer, more effective alternatives, especially in a chronic setting.
- Its role in contemporary asthma and COPD management guidelines has diminished due to the advent of newer, more targeted, and safer therapeutic options.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of aminophylline hydrate is highly individualized and complex, requiring careful titration based on clinical response, patient characteristics, and, most critically, serum theophylline concentrations. Due to its narrow therapeutic index, therapeutic drug monitoring (TDM) is essential to maximize efficacy while minimizing toxicity. Typically, a loading dose is administered to rapidly achieve therapeutic serum levels, followed by a maintenance infusion. The loading dose is generally calculated based on lean body weight and adjusted for patients who have recently received other theophylline products. Maintenance doses vary significantly depending on age, liver and renal function, heart failure, concurrent medications (e.g., cimetidine, erythromycin, phenobarbital, phenytoin, rifampin), smoking status, and other factors that influence drug metabolism and clearance. For instance, children and smokers generally require higher doses per kilogram due to faster metabolism, while the elderly and patients with hepatic or cardiac dysfunction require lower doses. Serum theophylline levels should be measured frequently, particularly after initiating therapy, changing dosage, or in the presence of signs of toxicity, aiming for a therapeutic range typically between 10-20 mcg/mL, though some guidelines suggest a narrower range of 5-15 mcg/mL for improved safety margins, especially in chronic use. Dosage adjustments must be made incrementally and under strict medical supervision. |
Safety & Warnings
Common Side Effects
- Aminophylline hydrate is associated with a range of dose-dependent side effects, which can become severe and life-threatening at toxic serum concentrations.
- Common adverse reactions include gastrointestinal disturbances such as nausea, vomiting, abdominal pain, diarrhea, and dyspepsia.
- Central nervous system effects are also prevalent and can manifest as headache, dizziness, insomnia, irritability, restlessness, tremors, and in more severe cases, seizures.
- Cardiovascular side effects can include palpitations, tachycardia, arrhythmias (e.
- g.
- , supraventricular tachycardia, ventricular ectopy), and hypotension, particularly with rapid intravenous administration.
- Other potential side effects include diuresis, muscle twitching, and hyperglycemia.
- The severity and incidence of these side effects increase sharply as serum theophylline levels exceed the therapeutic range.
- Therefore, close monitoring for these symptoms, alongside therapeutic drug monitoring, is imperative.
- Patients should be educated on recognizing early signs of toxicity and reporting them promptly to their healthcare provider to prevent more serious complications.
- The risk of these adverse effects underscores the need for careful dosage individualization and continuous patient assessment during treatment.
Serious Warnings
- Black Box Warning: Aminophylline hydrate does not carry a formal Black Box Warning issued by the U.S. Food and Drug Administration (FDA). However, due to its narrow therapeutic index and the significant potential for severe, life-threatening adverse effects, **Serious Warnings** are imperative for its safe use. **Therapeutic Drug Monitoring (TDM) is essential:** The difference between therapeutic and toxic concentrations of aminophylline is small. Serious adverse events, including seizures, cardiac arrhythmias (e.g., ventricular tachycardia, fibrillation), and sudden death, can occur at serum concentrations only slightly above the therapeutic range (typically >20 mcg/mL, though adverse effects may occur within this range). Factors such as age, liver disease, heart failure, fever, acute viral illnesses, hypothyroidism, and concurrent medications (e.g., macrolides, quinolones, cimetidine) significantly alter theophylline metabolism, necessitating frequent and careful monitoring of serum levels and dosage adjustments. **Risk of Toxicity:** Patients should be closely observed for signs of toxicity, including persistent vomiting, central nervous system stimulation (e.g., severe restlessness, seizures), and cardiac irregularities. Rapid intravenous administration can induce severe hypotension, cardiac arrhythmias, and even cardiac arrest. Therefore, administration must be slow and controlled. Healthcare providers must exercise extreme caution in dose selection and patient management, educating patients on the importance of adherence, recognizing early symptoms of toxicity, and avoiding concomitant use of other xanthine-containing products or medications that interact with aminophylline.
- Aminophylline hydrate carries significant warnings due to its narrow therapeutic index and the potential for severe, life-threatening adverse reactions.
- Therapeutic drug monitoring (TDM) of serum theophylline levels is crucial to prevent toxicity, as there is a small difference between therapeutic and toxic concentrations.
- Factors that can alter aminophylline clearance and necessitate dosage adjustments include age (neonates, elderly), liver dysfunction, heart failure, fever, acute viral illnesses, hypothyroidism, and concurrent medications (e.
- g.
- , cimetidine, macrolide antibiotics, quinolones, beta-blockers, phenobarbital, phenytoin, rifampin).
- Smoking status significantly impacts clearance; smokers often require higher doses, while smoking cessation necessitates dose reduction.
- Aminophylline should be used with extreme caution in patients with cardiovascular disease (e.
- g.
- , arrhythmias, severe hypertension, acute myocardial injury), peptic ulcer disease, seizure disorders, or hyperthyroidism, as it can exacerbate these conditions.
- Rapid intravenous administration can lead to hypotension, cardiac arrhythmias, and sudden cardiac arrest.
- Patients should be closely monitored for signs of toxicity, such as persistent vomiting, neurological symptoms (e.
- g.
- , seizures), and cardiac arrhythmias.
- Pediatric patients, especially neonates, and geriatric patients are particularly vulnerable to adverse effects and require meticulous dose titration and monitoring.
- Pregnancy and lactation also require careful consideration due to potential risks to the fetus or infant.
How it Works (Mechanism of Action)
Aminophylline hydrate exerts its therapeutic effects primarily through non-selective inhibition of phosphodiesterase (PDE) enzymes, particularly PDE3 and PDE4. This inhibition leads to an increase in intracellular cyclic adenosine monophosphate (cAMP) levels within bronchial smooth muscle cells. Elevated cAMP activates protein kinase A, which in turn phosphorylates various proteins, leading to a decrease in intracellular calcium concentrations and subsequent relaxation of bronchial smooth muscle, resulting in bronchodilation. Beyond its phosphodiesterase inhibitory effects, aminophylline also acts as a non-selective adenosine receptor antagonist. Adenosine is known to induce bronchoconstriction and inflammation, and by blocking its receptors, aminophylline further contributes to its bronchodilator and potentially anti-inflammatory actions. While less prominent, other proposed mechanisms include enhanced diaphragm contractility, stimulation of respiratory drive, and some anti-inflammatory effects through inhibition of inflammatory cell function and modulation of cytokine release. These multiple mechanisms contribute to its efficacy in managing reversible airway obstruction, although its broad activity also contributes to its diverse side effect profile.
Commercial Brands (Alternatives)
No other brands found for this formula.